Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Market Access and Reimbursement Insights Report – 2025

Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Market Access and Reimbursement Insights

Thelansis’s “Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) Overview

Relapsed or refractory myelodysplastic syndromes represent a group of clonal bone marrow disorders characterized by ineffective hematopoiesis, cytopenias, and risk of progression to acute myeloid leukemia. Patients with R/R MDS have either failed to respond to initial therapies, most commonly hypomethylating agents such as azacitidine or decitabine, or have relapsed after an initial response. Clinically, these patients experience persistent anemia, infections due to neutropenia, and bleeding complications from thrombocytopenia, all of which contribute to poor quality of life and high healthcare utilization. Treatment options are limited, with allogeneic stem cell transplantation being the only potentially curative approach, though many patients are ineligible due to age or comorbidities. Novel agents targeting epigenetic pathways, apoptosis regulators, and immune checkpoints are under investigation, but outcomes remain poor and survival is short once standard therapies fail. The lack of effective salvage options highlights a significant unmet need for innovative therapies that can improve survival and alter disease progression, making R/R MDS a critical focus area in hematology drug development.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Relapsed or Refractory Myelodysplastic Syndromes (R/R MDS) – Market Access and Reimbursement Insights Report – 2025